- Home
- REX vs PLRX Comparison
REX vs PLRX Comparison
Compare REX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REX
- PLRX
- Stock Information
- Founded
- REX 1980
- PLRX 2015
- Country
- REX United States
- PLRX United States
- Employees
- REX N/A
- PLRX N/A
- Industry
- REX Major Chemicals
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- REX Industrials
- PLRX Health Care
- Exchange
- REX Nasdaq
- PLRX Nasdaq
- Market Cap
- REX 847.7M
- PLRX 89.0M
- IPO Year
- REX N/A
- PLRX 2020
- Fundamental
- Price
- REX $30.50
- PLRX $1.54
- Analyst Decision
- REX Strong Buy
- PLRX Hold
- Analyst Count
- REX 1
- PLRX 10
- Target Price
- REX $25.00
- PLRX $3.93
- AVG Volume (30 Days)
- REX 119.5K
- PLRX 725.5K
- Earning Date
- REX 08-27-2025
- PLRX 11-06-2025
- Dividend Yield
- REX N/A
- PLRX N/A
- EPS Growth
- REX N/A
- PLRX N/A
- EPS
- REX 2.98
- PLRX N/A
- Revenue
- REX $650,008,000.00
- PLRX N/A
- Revenue This Year
- REX $3.27
- PLRX N/A
- Revenue Next Year
- REX $17.11
- PLRX N/A
- P/E Ratio
- REX $20.38
- PLRX N/A
- Revenue Growth
- REX N/A
- PLRX N/A
- 52 Week Low
- REX $33.45
- PLRX $1.10
- 52 Week High
- REX $64.95
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- REX 15.59
- PLRX 50.38
- Support Level
- REX $60.39
- PLRX N/A
- Resistance Level
- REX $62.30
- PLRX $1.85
- Average True Range (ATR)
- REX 1.82
- PLRX 0.12
- MACD
- REX -2.34
- PLRX -0.08
- Stochastic Oscillator
- REX 0.74
- PLRX 81.22
About REX REX American Resources Corporation
REX American Resources Corp operates as a holding company, which engages in investment in alternative energy and ethanol production entities. Its operating segments include Ethanol and By-Products. Its products include dried distillers grains, modified distillers grains, and non-food grade corn oil.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.